CQ 32085 (mesulergine)

01/01/1986 - "Used as sole therapeutic agent (10.9 mg/day), mesulergine was found to be active on tremor and rigidity scores but not on akinesia or global scores. "
03/04/1985 - "CU 32-085 relieves tremor in monkeys with ventromedial tegmental lesions and produces only slight abnormal involuntary movements. "
01/01/1983 - "With a mean daily dose of 12.65 mg, CU 32-085 together with levodopa plus a decarboxylase inhibitor produced a significant reduction in akinesia, rigor and tremor. "
01/01/1986 - "These results show the antiparkinsonian properties of mesulergine that seem to be of significant therapeutic value in patients with tremor or in combination with levodopa."
01/01/1983 - "The administration of pergolide or LY 141865 results in a relief of tremor with a concomitant occurrence of severe abnormal involuntary movements, while the administration of CU 32-085 results in a relief of tremor with the occurrence of only minor abnormal involuntary movements. "

04/01/1986 - "Mesulergine in early Parkinson's disease: a double blind controlled trial."
08/01/1985 - "Previous studies with mesulergine (CU 32-085) demonstrated safety and efficacy in short-term observations of patients with Parkinson's disease. "
02/01/1985 - "Placebo-controlled study of mesulergine in Parkinson's disease."
11/01/2000 - "[3H]-mesulergine binding was increased in the substantia nigra pars reticulata by 108% in Parkinson's disease tissue as compared with control tissue. "
04/01/1986 - "It is suggested that Mesulergine derivatives might well be of value in future treatment of early Parkinson's disease and of late incompensated stages."

01/01/1985 - "Dyskinesias were not seen during monotherapy with mesulergine in de novo patients."
03/04/1985 - "CU 32-085 relieves tremor in monkeys with ventromedial tegmental lesions and produces only slight abnormal involuntary movements. "
01/01/1986 - "The decrease in levodopa dose and the addition of mesulergine permitted a significant reduction in dyskinesia. "
03/04/1985 - "Studies in monkeys with ventromedial tegmental lesions suggest that CU 32-085 might be an effective antiparkinsonian agent which produces less dyskinesias than the other tested dopamine agonists."
01/01/1986 - "Adverse effects (dyskinesias) were less with mesulergine than with pergolide. "

01/01/1982 - "Both compounds were useful in the management of patients with advanced Parkinson's disease, CU 32-085 having a stronger effect on tremor, bradykinesia, fluctuations and "on-off' effects than bromocriptine."

05/01/1985 - "Mesulergine was given to 22 women and five men with hyperprolactinaemia. "
05/01/1985 - "Comparison of the clinical activity of mesulergine and pergolide in the treatment of hyperprolactinaemia."
11/01/1984 - "In a blind crossover study in six subjects with hyperprolactinemia, 0.5 mg mesulergine induced fewer side effects than did 2.5 mg bromocriptine, while the PRL release-inhibiting effect of the two was of the same order. "
11/01/1984 - "Because of its acceptability, mesulergine might be important in the treatment of hyperprolactinemia and perhaps also of acromegaly and Parkinson's disease."
03/01/1992 - "Since no data are yet available on the effects of mesulergine on pituitary dopamine receptors, the present study has been designated to elucidate the influence of this drug on prolactin secretion in vivo and in vitro and 3H-spiperone binding by the anterior pituitary gland in female Wistar rats with experimentally induced hyperprolactinemia. "